Association for the Advancement of Wound Care

Dr. John C. Lantis named Editor-in-Chief of HMP Global's WOUNDS journal; Dr. Terry Treadwell transitions to Editor-in-Chief Emeritus

Retrieved on: 
Tuesday, May 30, 2023
Lantis, Biochemistry, Editorial board, MEDLINE, World Association of Medical Editors, WHS, Podiatry, Patient, Greater New York, Virginia School for Girls, Heart, Vice, University, Physician, Research, Strategic planning, University of Virginia School of Medicine, American Board of Commissioners for Foreign Missions, Regeneration, Biology, Wound healing, National Harbor, Maryland, Abstract, SAWC, Morningside Hospital (Oregon), Baptist Medical Center, Assistant, Publication, Symposium, Association for the Advancement of Wound Care, History, PM, Icahn School of Medicine at Mount Sinai, DLS, World Association for Medical Law, Medical director, Management, Medical device, Nursing, Journal, D.C, Autumn, Mount Sinai West, Wound

MALVERN, Pa., May 30, 2023 /PRNewswire-PRWeb/ -- HMP Global's industry-leading journal WOUNDS today announced that Dr. John C. Lantis II is the new Editor-in-Chief, with Dr. Terry Treadwell transitioning to the role of Editor-in-Chief Emeritus. The journal has also announced that Dr. Vickie R. Driver will be named as a Clinical Editor. The new leadership will guide the journal's management and strategic planning as the premier peer-reviewed publication features a growing body of practice-changing research in wound care.

Key Points: 
  • MALVERN, Pa., May 30, 2023 /PRNewswire-PRWeb/ -- HMP Global's industry-leading journal WOUNDS today announced that Dr. John C. Lantis II is the new Editor-in-Chief, with Dr. Terry Treadwell transitioning to the role of Editor-in-Chief Emeritus.
  • The journal has also announced that Dr. Vickie R. Driver will be named as a Clinical Editor.
  • Dr. Lantis is the Site-Chief of Surgery at the Mount Sinai West Hospital and professor of surgery at the Icahn School of Medicine at Mount Sinai.
  • Dr. Treadwell first joined the WOUNDS Editorial Advisory Board in 2002 and has been the Editor since January 2007.

STUDY FINDS VOMARIS BIOELECTRIC TECHNOLOGY SIGNIFICANTLY DECREASED BIOFILM IN BURN PATIENTS

Retrieved on: 
Wednesday, March 15, 2023
Walter Reed Army Institute of Research, TEWL, Microcurrent electrical neuromuscular stimulator, Burns, Bacteria, Burn, Fig, Annals of Surgery, BAMC, Standard of care, Manuscript, Infection, Burn center, SOC, Indiana University, Brooke Army Medical Center, Patient, Death, Effectiveness, Association for the Advancement of Wound Care, Incidence, Control, Doctor of Philosophy, Journal of Surgical Research, Pharmaceutical industry, Vaccine

1) significantly decreased biofilm presence and severity in all burn wound patients (Fig.

Key Points: 
  • 1) significantly decreased biofilm presence and severity in all burn wound patients (Fig.
  • In addition, the Vomaris dressing significantly decreased the incidence of specific opportunistic bacterial pathogen strains in burn patients (Fig.
  • The bioelectric dressing technology is an important new tool for addressing the significant challenge of biofilm infection," commented Dr. Chan.
  • V.Dox Technology offers clinicians and patients an easy-to-use, economical, one-of-a-kind solution to help combat the threat of biofilm infection," said Vomaris President and CEO Michael Nagel.

FDA clears first placental extracellular matrix medical device for management of second-degree burns

Retrieved on: 
Thursday, March 2, 2023
ECM, Safety, Multimedia, Convatec, Burn, AC, FDA, Burns, Orientation, System, Diet, Virus, Regenerative medicine, Patient, Association for the Advancement of Wound Care, Korea Disease Control and Prevention Agency, Medicine, Skin, American Burn Association, Regulation of tobacco by the U.S. Food and Drug Administration, Nursing care plan, FS, Medicare, Mouth ulcer, PD, Pressure, Food, FTSE, Wound, Compendium, LSE, Medical device, Nursing, Pharmaceutical industry

MEMPHIS, Tenn., March 2, 2023 /PRNewswire/ -- Convatec has received clearance from the U.S. Food and Drug Administration for its InnovaBurn® placental extracellular matrix medical device for management of complex surgical wounds and burns, including partial-thickness second-degree burns.

Key Points: 
  • MEMPHIS, Tenn., March 2, 2023 /PRNewswire/ -- Convatec has received clearance from the U.S. Food and Drug Administration for its InnovaBurn® placental extracellular matrix medical device for management of complex surgical wounds and burns, including partial-thickness second-degree burns.
  • The InnovaBurn® medical device joins Convatec's InnovaMatrix® platform as the first and only placental-derived medical devices designed for management of burns, complex surgical wounds and hard-to-heal wounds.
  • Manufactured with Convatec's proprietary TriCleanse™ Process, InnovaMatrix® products, including the new InnovaBurn® ECM, give physicians a next-generation medical device that preserves the inherent benefits of the placenta along with the reliability, reproducibility, and safety of a medical device.
  • "InnovaBurn® is an innovative advancement in ECM technology for patients with partial-thickness, second-degree burns," said Debra Noble, sales director of Convatec's U.S.

FDA clears first particulate placental extracellular matrix medical device for wound management

Retrieved on: 
Thursday, February 23, 2023
Skin, FTSE, PD, System, Mouth ulcer, Convatec, Virus, Association for the Advancement of Wound Care, Nursing care plan, Pressure, FDA, ECM, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, Diet, Regenerative medicine, Burns, LSE, Medicare, Wound, Compendium, Medicine, AC, Multimedia, Quality control, Food, Physician, Placenta, Pharmaceutical industry, Electric motor, Medical device

MEMPHIS, Tenn., Feb. 23, 2023 /PRNewswire/ -- Convatec today announced it has received clearance from the U.S. Food and Drug Administration for its InnovaMatrix® PD particulate placental extracellular matrix medical device for wound management.

Key Points: 
  • MEMPHIS, Tenn., Feb. 23, 2023 /PRNewswire/ -- Convatec today announced it has received clearance from the U.S. Food and Drug Administration for its InnovaMatrix® PD particulate placental extracellular matrix medical device for wound management.
  • The medical device joins Convatec's existing InnovaMatrix® AC product as the first and only next-generation placental-derived medical devices designed for management of complex surgical wounds, chronic stalled wounds and burns.
  • It gives physicians a placental-derived particulate product that can replace the human particulate placenta products no longer on the market.
  • It offers the inherent benefits of the placenta plus the quality control, reliability and safety profile of a medical device.

Net Health Research into Machine Learning for Wound Care Highlighted in Leading Journal

Retrieved on: 
Tuesday, October 26, 2021
Compliance, Quality of life, Hospital, Hypertension, Article (publishing), Workflow, Net Health, Organization, Caregiver, Patient, Machine learning, View, Occupational medicine, Time, BSN, The Carlyle Group, Precision medicine, Software, Association for the Advancement of Wound Care, EHR, Documentation, Multimedia, Health, Diabetes, Artificial intelligence, Wound healing, Journal, AI, Medical device, Medicine

Net Health is a leading provider of cloud-based software and analytics for specialty medical providers, including wound care, rehabilitation therapy, home health and hospice, and occupational medicine.

Key Points: 
  • Net Health is a leading provider of cloud-based software and analytics for specialty medical providers, including wound care, rehabilitation therapy, home health and hospice, and occupational medicine.
  • The company provides several software applications and services for the wound care industry, including the leading electronic health record (EHR) system for hospitals and clinics and related services.
  • For the study, clinicians and data scientists used information from Net Health's Wound Care EHR to predict the likelihood of a patient's wound healing in 4, 8, and 12 weeks from the start of treatment.
  • "Wound care costs the nation tens of billions of dollars each year," said first author Matt Berezo, a Data Scientist with Net Health .

AOTI Participating in Multiple Leading Global Wound Care Conferences

Retrieved on: 
Tuesday, October 12, 2021
Medical director, IDF, Association for the Advancement of Wound Care, AAWC, Mouth ulcer, Congress, Foot, RWE, Virtual, Ulcer, COVID-19, DFU, International Diabetes Federation, Diabetes, VLU, Telehealth, Society, Quality of life, CME, RCT, CEO, European Wound Management Association, Association, EWMA, Patient, Diabetic foot, Wound healing, Research, Medicine, Pharmaceutical industry

OCEANSIDE, Calif., Oct. 12, 2021 /PRNewswire/-- Advanced Oxygen Therapy Inc. (AOTI) announced that it is proud to be supporting multiple leading global continuing medical education (CME) eligible wound care conferences across the remainder of 2021.

Key Points: 
  • OCEANSIDE, Calif., Oct. 12, 2021 /PRNewswire/-- Advanced Oxygen Therapy Inc. (AOTI) announced that it is proud to be supporting multiple leading global continuing medical education (CME) eligible wound care conferences across the remainder of 2021.
  • This time, participants from USA and Canada can register free of charge, due to an unrestricted grant provided by AOTI.
  • The Desert Foot Virtual Limb Salvage and Wound Care congress is held jointly with the Association for the Advancement of Wound Care (AAWC) from December 3 - 11, 2021.
  • Our patented non-invasive Topical Wound Oxygen (TWO2) therapy is Proven to Deliver Sustained Wound Healing, So Life Can Get Back to Normal

Dr. Thomas Serena, MD, FACS, FACHM, MAPWCA Has Agreed to be MDM Wound Ventures, Inc's Clinical and Research Director

Retrieved on: 
Wednesday, September 22, 2021
United States, Wound, AAWC, Wound healing, Multimedia, Medical director, Hyperbaric medicine, Association, American College, Board, Association for the Advancement of Wound Care, Principal, SAN, Research, Lead, MDM, American, CTP, Medicine

SAN ANTONIO, Sept. 22, 2021 /PRNewswire/ -- MDM Wound Ventures Inc., the manufacturer of EZ Debride, is announcing Dr. Thomas Serena has agreed to the position of Clinical and Research Director at MDM Wound Ventures, Inc. Dr. Thomas E. Serena MD FACS FACHM MAPWCA, Founder and Medical Director of The SerenaGroup, a family of wound, hyperbaric and research companies.

Key Points: 
  • SAN ANTONIO, Sept. 22, 2021 /PRNewswire/ -- MDM Wound Ventures Inc., the manufacturer of EZ Debride, is announcing Dr. Thomas Serena has agreed to the position of Clinical and Research Director at MDM Wound Ventures, Inc. Dr. Thomas E. Serena MD FACS FACHM MAPWCA, Founder and Medical Director of The SerenaGroup, a family of wound, hyperbaric and research companies.
  • To date he has opened and operates wound care centers across the United Sates and globally.
  • MDM Wound Ventures, Inc., develops and manufactures innovative and disruptive products for diabetic limb salvage and advanced wound care clinicians and providers, globally.
  • For more information about EZ Debride or MDM Wound Ventures Inc., or to book a clinical visit and demonstration please contact:
    View original content to download multimedia: https://www.prnewswire.com/news-releases/dr-thomas-serena-md-facs-fachm-...